Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
about
Systemic delivery of oncolytic viruses: hopes and hurdlesImmune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancersImproved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2Intelligent design: combination therapy with oncolytic virusesClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityTo Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerClinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Modification of mammalian reoviruses for use as oncolytic agentsPrime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyCycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamstersCurrent issues and future directions of oncolytic adenoviruses.Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing miceVSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.Gene therapy progress and prospects cancer: oncolytic viruses.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium reportCytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsPhase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escapePolymeric oncolytic adenovirus for cancer gene therapy.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumorCombination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesThe Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentChimeric antigen receptor-engineered T cells as oncolytic virus carriers.Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Reovirus serotypes elicit distinctive patterns of recall immunity in humansReolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.Oncolytic measles virus strains as novel anticancer agents.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Oncolytic viruses: a novel form of immunotherapy.Reovirus: a targeted therapeutic--progress and potential.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Pharmacologic and chemical adjuvants in tumor virotherapy.
P2860
Q21284969-5D7FE857-232B-4E99-963E-A1EC8AF97C5EQ24596171-52B12810-596A-48D0-9A92-E8CBE1C2BC25Q24611483-09843C41-E8E3-4007-A91F-849B25031B19Q24612603-270B270B-AA9A-4E6D-8A3B-079FE93ED22EQ24628227-493622E1-244B-4E59-927A-53E43E122A45Q26750568-B87DB895-6FDD-4D47-BBCE-1C297ACE39F9Q26767212-4723782F-EDFD-435F-8483-2014BDA33051Q26863779-D0405F42-E2F8-4C97-B90A-84640DC3162BQ27021839-AD51B0F5-C67B-4A3C-9BD1-720A7E8663E8Q27690634-19091D5E-8BB9-44C7-8977-323C88572DE3Q28264900-22949DA6-6588-407D-9BE5-D22D0045A524Q33551626-A53AC656-904D-4556-A6E0-EF0DEB8C8500Q33580223-B1674ED6-2D65-4E0E-A7FA-7A582ABF1F6CQ33730705-0C2E2497-BC46-4AED-A77F-F3E02F0B9C88Q33815701-B832CDE5-F46E-4D78-924A-6742321B21FDQ33906116-D15F983D-9AB0-4BEB-86A6-A5E361E8FDE4Q33927165-B4534B7E-8684-459B-A27B-60268375B79EQ34473352-AF7DC356-1274-4C69-95B6-0B73619C06F4Q34770611-5EAB7FC9-B9C3-40E6-8AA9-25298E0DCC20Q35224368-A749C64A-CE42-400F-924F-385FA9E14D29Q35596563-CDE5FDB8-DC0F-4E78-A0DC-A52431A4B50AQ35687743-7645D0DE-3557-455A-828C-85E38A327B44Q36298608-983D3EA0-D31E-4BF1-B4F1-BA60F4C4DC5EQ36321054-9E4EF5CC-5EA2-435D-8256-65E65A790748Q36344901-C8140AF3-A1B4-4A0C-B329-DFA1331A7231Q36390114-24FF4603-2D89-47E7-8B76-2FD4DFF0C48FQ36582819-CE52E9C1-361A-4527-A718-575F6790E631Q36658280-78F16B8F-73B0-43C9-9DE5-DC8B2493C1F4Q36664258-E13F5813-21BC-466D-A8D8-D37E34411C22Q36766032-8E6B3FE8-0145-4D2A-B7D1-297F9EC72136Q36804613-67423F5F-A389-4D58-BCDA-FE2EB18BE618Q37062074-B05FD652-BC19-4DAC-810B-24ECB2FEFAA1Q37185367-EF88A6E8-9F70-43CB-8A2B-BF1B6F37592BQ37239555-C95A7CAC-00E3-4462-8285-AAC9FC4F8A41Q37261017-ED196DDF-8D62-4665-931A-2E03000E9CA0Q37280354-3E7197BC-F04C-4167-9586-70DBE7775992Q37300008-84037D7F-64FA-4FB9-A96F-D25145BB2B6FQ37360608-73B25376-D693-42A8-A172-7A574AE8853AQ37459636-FB6A69E6-7B7C-4E67-BEB0-064B72E72979Q37492540-8438DF43-6EC8-4773-BED2-192F8D5260E8
P2860
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en-gb
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@nl
type
label
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en-gb
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@nl
prefLabel
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en-gb
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@nl
P2093
P2860
P1476
Cyclophosphamide facilitates a ...... ravenous delivery of reovirus.
@en
P2093
Christine White
Hardev Pandha
Hongxun Wang
Jill Thompson
Johann de Bono
Katie Twigger
Kevin Harrington
Matt Coffey
Richard Vile
P2860
P304
P356
10.1158/1078-0432.CCR-07-1510
P407
P577
2008-01-01T00:00:00Z